Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion to Boost Endocrinology Portfolio

Neurocrine Biosciences has reached a definitive agreement to acquire Soleno Therapeutics for $53.00 per share, totaling an equity value of $2.9 billion. This strategic acquisition aims to enhance Neurocrine's position in endocrinology and rare diseases by integrating VYKAT™ XR (diazoxide choline), the sole FDA-approved treatment for hyperphagia associated with Prader-Willi syndrome (PWS).

The inclusion of VYKAT XR, which generated substantial early revenue with $190 million projected for 2025, is expected to significantly accelerate Neurocrine's revenue growth, augmenting its lineup of first-in-class medicines. Neurocrine anticipates that this acquisition not only diversifies its existing portfolio but also reinforces its ongoing mission to provide transformative therapies to patients with rare diseases.

Strengthening Neurocrine's Portfolio

Post-acquisition, Neurocrine will have three first-in-class therapies: INGREZZA®, projected to generate $2.51 billion in revenue for 2025, CRENESSITY® with $301 million expected, and the newly added VYKAT XR. This growing portfolio is expected to play a crucial role in the company’s strategy to meet the needs of rare disease patients and enhance care.

Future Growth Opportunities

Both CEOs of Neurocrine and Soleno express confidence that Neurocrine's strong infrastructure will effectively expand VYKAT XR's reach within the PWS community. They believe this enhancement is pivotal in improving patient care and aligning with the company’s long-term growth strategy.